NO20031185L - Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel - Google Patents
Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddelInfo
- Publication number
- NO20031185L NO20031185L NO20031185A NO20031185A NO20031185L NO 20031185 L NO20031185 L NO 20031185L NO 20031185 A NO20031185 A NO 20031185A NO 20031185 A NO20031185 A NO 20031185A NO 20031185 L NO20031185 L NO 20031185L
- Authority
- NO
- Norway
- Prior art keywords
- cytokine
- selectokine
- antibody
- target
- fusion protein
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10045592A DE10045592A1 (de) | 2000-09-15 | 2000-09-15 | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
| PCT/EP2001/010730 WO2002022833A1 (de) | 2000-09-15 | 2001-09-17 | Fusionsprotein aus antikörper-zytokin-zytokin inhibitor (selektokin) als zielspezifisches prodrug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20031185D0 NO20031185D0 (no) | 2003-03-14 |
| NO20031185L true NO20031185L (no) | 2003-05-05 |
Family
ID=7656260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20031185A NO20031185L (no) | 2000-09-15 | 2003-03-14 | Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20040053829A1 (no) |
| EP (1) | EP1317556A1 (no) |
| JP (1) | JP2004508828A (no) |
| KR (1) | KR20030048041A (no) |
| CN (1) | CN1214115C (no) |
| AU (1) | AU2001293819A1 (no) |
| BG (1) | BG107613A (no) |
| BR (1) | BR0113928A (no) |
| CA (1) | CA2422759A1 (no) |
| DE (1) | DE10045592A1 (no) |
| EE (1) | EE200300100A (no) |
| HR (1) | HRP20030192A2 (no) |
| HU (1) | HUP0301693A3 (no) |
| IL (1) | IL154185A0 (no) |
| MX (1) | MXPA03002229A (no) |
| NO (1) | NO20031185L (no) |
| PL (1) | PL360540A1 (no) |
| RU (1) | RU2003106429A (no) |
| SK (1) | SK2812003A3 (no) |
| WO (1) | WO2002022833A1 (no) |
| YU (1) | YU18903A (no) |
| ZA (1) | ZA200302008B (no) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002043773A2 (en) * | 2000-12-01 | 2002-06-06 | The Johns Hopkins University | Tissue specific prodrugs |
| PE20021080A1 (es) * | 2001-04-12 | 2003-02-12 | Boehringer Ingelheim Int | Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer |
| DE10144252A1 (de) * | 2001-08-31 | 2003-03-27 | Fraunhofer Ges Forschung | Nanopartikel mit daran immobilisiertem biologisch aktivem TNF |
| DE10247755B4 (de) * | 2002-10-14 | 2006-01-19 | Pfizenmaier, Klaus, Prof. Dr. | Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine |
| CA2515100A1 (en) * | 2003-02-06 | 2004-08-19 | Micromet Ag | Trimeric polypeptide construct to induce an enduring t cell response |
| US7374898B2 (en) * | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
| US20090041783A1 (en) | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
| EP1736482A1 (en) * | 2005-06-20 | 2006-12-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Recombinant trimeric 4-1BBL |
| DE102005036542A1 (de) * | 2005-08-03 | 2007-02-08 | Universität Stuttgart | CTL-Prodrug |
| EP1972350A1 (en) * | 2007-03-20 | 2008-09-24 | Rijksuniversiteit Groningen | Dual targeting system |
| EP2009022A1 (en) * | 2007-06-26 | 2008-12-31 | Apogenix GmbH | Trimeric death ligands with enhanced activity (tenascin) |
| CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| CN102482347B (zh) | 2009-01-12 | 2017-04-26 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| JP7515412B2 (ja) * | 2018-03-09 | 2024-07-12 | アスクジーン・ファーマ・インコーポレイテッド | 新規のサイトカインプロドラッグ |
| CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
| WO2019222294A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| JP2021530243A (ja) * | 2018-07-25 | 2021-11-11 | アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. | 新規ｉｌ−２１プロドラッグおよびそれを使用する方法 |
| BR112021005907A2 (pt) | 2018-09-27 | 2021-08-10 | Xilio Development, Inc. | citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit |
| SG11202112541RA (en) | 2019-05-14 | 2021-12-30 | Werewolf Therapeutics Inc | Separation moieties and methods and use thereof |
| WO2020252264A1 (en) * | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| KR20220101147A (ko) | 2019-11-14 | 2022-07-19 | 웨어울프 세라퓨틱스, 인크. | 활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981001145A1 (en) * | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US5502037A (en) * | 1993-07-09 | 1996-03-26 | Neuromed Technologies, Inc. | Pro-cytotoxic drug conjugates for anticancer therapy |
| US5763733A (en) * | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
| US5614191A (en) * | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| DE19900709A1 (de) * | 1999-01-11 | 2000-07-13 | Falkenberg Frank W | Eine neue Applikationsform für biologisch wirksame Substanzen zur Anwendung bei Menschen und Tieren |
-
2000
- 2000-09-15 DE DE10045592A patent/DE10045592A1/de not_active Withdrawn
-
2001
- 2001-09-17 SK SK281-2003A patent/SK2812003A3/sk unknown
- 2001-09-17 HU HU0301693A patent/HUP0301693A3/hu unknown
- 2001-09-17 US US10/380,438 patent/US20040053829A1/en not_active Abandoned
- 2001-09-17 JP JP2002527275A patent/JP2004508828A/ja active Pending
- 2001-09-17 BR BR0113928-2A patent/BR0113928A/pt not_active IP Right Cessation
- 2001-09-17 RU RU2003106429/13A patent/RU2003106429A/ru not_active Application Discontinuation
- 2001-09-17 EE EEP200300100A patent/EE200300100A/xx unknown
- 2001-09-17 CN CNB018157645A patent/CN1214115C/zh not_active Expired - Fee Related
- 2001-09-17 AU AU2001293819A patent/AU2001293819A1/en not_active Abandoned
- 2001-09-17 KR KR10-2003-7003738A patent/KR20030048041A/ko not_active Application Discontinuation
- 2001-09-17 MX MXPA03002229A patent/MXPA03002229A/es unknown
- 2001-09-17 WO PCT/EP2001/010730 patent/WO2002022833A1/de active Application Filing
- 2001-09-17 CA CA002422759A patent/CA2422759A1/en not_active Abandoned
- 2001-09-17 PL PL36054001A patent/PL360540A1/xx not_active Application Discontinuation
- 2001-09-17 EP EP01974261A patent/EP1317556A1/de not_active Withdrawn
- 2001-09-17 YU YU18903A patent/YU18903A/sh unknown
- 2001-09-17 IL IL15418501A patent/IL154185A0/xx unknown
-
2003
- 2003-03-06 BG BG107613A patent/BG107613A/bg unknown
- 2003-03-12 ZA ZA200302008A patent/ZA200302008B/en unknown
- 2003-03-14 HR HR20030192A patent/HRP20030192A2/hr not_active Application Discontinuation
- 2003-03-14 NO NO20031185A patent/NO20031185L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20031185D0 (no) | 2003-03-14 |
| BR0113928A (pt) | 2003-07-22 |
| HRP20030192A2 (en) | 2005-10-31 |
| YU18903A (sh) | 2006-05-25 |
| WO2002022833A1 (de) | 2002-03-21 |
| SK2812003A3 (en) | 2003-11-04 |
| JP2004508828A (ja) | 2004-03-25 |
| CN1214115C (zh) | 2005-08-10 |
| CA2422759A1 (en) | 2003-03-17 |
| AU2001293819A1 (en) | 2002-03-26 |
| IL154185A0 (en) | 2003-07-31 |
| RU2003106429A (ru) | 2004-08-27 |
| EE200300100A (et) | 2005-02-15 |
| HUP0301693A3 (en) | 2005-11-28 |
| US20040053829A1 (en) | 2004-03-18 |
| DE10045592A1 (de) | 2002-03-28 |
| EP1317556A1 (de) | 2003-06-11 |
| ZA200302008B (en) | 2004-06-25 |
| CN1458977A (zh) | 2003-11-26 |
| BG107613A (bg) | 2003-12-31 |
| KR20030048041A (ko) | 2003-06-18 |
| HUP0301693A2 (hu) | 2003-08-28 |
| PL360540A1 (en) | 2004-09-06 |
| MXPA03002229A (es) | 2005-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20031185L (no) | Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel | |
| NO20030055D0 (no) | Colchinolderivater som angiogenese inhibitorer | |
| ATE437862T1 (de) | Pyrimidin-5-onderivate als ldl-pla2 inhibitoren | |
| DK2253620T3 (da) | Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer | |
| DK1286989T3 (da) | Prodrug fra en ICE | |
| ATE288437T1 (de) | Tetrahydro-heterocycloazepinyl-pyrimidin-deriva e | |
| DE60136416D1 (de) | Kraftverstärkender Mechanismus für Hefter | |
| DE60115817D1 (de) | Nickel-Basis-Hartlotlegierung | |
| DE60129982D1 (de) | Schweisshemmende zusammensetzungen | |
| DE60116311D1 (de) | Schweisshemmende zusammensetzungen | |
| NO20016201D0 (no) | Tienopyrimidiner som fosfodiesteraseinhibitorer | |
| DE60017273D1 (de) | Laserschweisssystem | |
| DK1571140T3 (da) | Substituerede C-cyjklohexylmethylamin-derivater | |
| DK1442026T3 (da) | Triazolderivater som cyclooxygenase (COX)-inhibitorer | |
| ATE282021T1 (de) | Substituierte aminomethyl-phenyl- cyclohexanderivate | |
| ATE272045T1 (de) | Substituierte 1-aminobutan-3-ol-derivate | |
| IT250181Y1 (it) | Custodia perfezionata per rivoltella | |
| DE50112454D1 (de) | Substituierte 5-amino-1-penten-3-ol-derivate | |
| DE50107634D1 (de) | Faltschachtel | |
| DE60130423D1 (de) | Festkörperlaser | |
| DK1296981T3 (da) | Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer | |
| ITNO20000008A0 (it) | Progetto anubi | |
| DK1246793T3 (da) | Substituerede aminomethyl-phenyl-cyclohexanderivater | |
| FI20002674A0 (fi) | Rimarakennemuotti | |
| NO20010900D0 (no) | Oksamider som IMPDH-inhibitorer |